Our professionals

Dr. Sandra Hervás Stubbs

Principal investigator of the Adoptive Cell Therapy research group. .
Current research focused on improving the efficacy of T-cell therapy for the treatment of solid tumors, including CAR-T cells, but with special attention to the development of TCR therapies.

Be part of: Cima Universidad de Navarra
INDEX H 39

Professional career

  • Bachelor in Biological Sciences, Universidad de Navarra (Spain), 1990
  • PhD in Sciences, Universidad de Navarra (Spain), 1995
  • Research Assistant, Public University of Navarra (1996-2002)
  • Postoctoral, Dr. Claude Leclerc’s laboratoru, Pasteur Institute in Paris (France) (2003-2006)
  • Ramon y Cajal, Center for Applied Medical Researc, Universidad de Navarra (Spain), (2007-2012)
  • Principal Investigator, Center for Applied Medical Researc, Universidad de Navarra (Spain), (2013-)

RESEARCH AREAS

  • Development of therapeutic vaccines for the treatment of chronic hepatitis B
  • Role of IFN-I in the antitumor efficacy of virotherapy and adoptive cell therapy
  • Characterization of the antitumor immune response and mechanisms of tumor escape from immune surveillance
  • Monitoring immune response and searching for predictive biomarkers of responses in clinical trials
  • Co-inventor of two patents
  • She has participated in more than 20 research projects, serving as principal investigator in 11 of them. Notable are the competitive projects funded by: Instituto de Salud Carlos III, Government of Navarra, Ministry of Science and Innovation, Ministry of Economy and Competitiveness, European Union, Spanish Association Against Cancer, and private organizations. 
  • She has established 2 agreements and collaborations with R&D&I centers.

AREAS OF INTEREST

  • Development of personalized TCR cellular therapies 
  • Enhancement of CAR-T therapy through combination with immunomodulators, vaccines, and radiotherapy
  • Identification of tumor neoantigens and analysis of their value as response biomarkers in clinical trials
  • T-cell immune monitoring in clinical trials by evaluating changes in the TCR repertoire

Activity

As an educator

  • She has supervised 3 doctoral theses, 2 of which were awarded the Extraordinary Doctorate Prize from the University of Navarra.
  • She has contributed to the writing of 2 books.
  • Associate Professor for the Expert Degree in Immuno-Oncology at Bristol Myers Squibb and the Faculty of Medicine of the University of Navarra. 
  • Invited speaker at more than 10 courses and symposia over the past 5 years. Of note: Invitation to the 10th International Forum on Translational Immunology and Cancer Immunotherapy, Seville, 2024.

As a researcher

  • She has contributed to the publication of more than 100 scientific articles in international journals and more than 90 presentations at national/international conferences.
  • Inventor of a TCR targeting the GPC3 tumor antigen for the treatment of hepatoblastomas and hepatocarcinomas. 
  • Participation in clinical trials monitoring immune response and seeking predictive biomarkers of responses. NASIR and ATHECA.
More information

Icono ORCID   ORCID

Icono RESEARCHID   RESEARCHID

Scopus   SCOPUS ID